Pleural Diseases Market Study Highlights How Industry Demand Is Evolving

The pleural diseases market is gearing up for significant expansion in the coming years, driven by advancements in diagnostics and treatment options. As healthcare continues to embrace precision medicine and less invasive procedures, this sector is poised for notable growth. Below is an overview of the market size projections, key players, emerging trends, and segmentation that define the future landscape of pleural disease management.

Forecasted Market Size of the Pleural Diseases Market by 2030
The pleural diseases market is projected to reach a value of $7.35 billion by 2030, growing at a compound annual growth rate (CAGR) of 7.1%. This upward trajectory is fueled by increasing investments in early cancer detection technologies, heightened demand for minimally invasive diagnostic approaches, expanded use of precision medicine, and a growing emphasis on outpatient respiratory care. Progress in pleural disease treatments also plays a significant role. Key trends anticipated during this period include wider implementation of advanced imaging diagnostics, greater adoption of minimally invasive pleural procedures, enhanced use of molecular diagnostic tools, broadening early detection initiatives, and an intensified focus on personalized therapeutic strategies.

The pleural diseases market size has grown strongly in recent years. It will grow from $5.21 billion in 2025 to $5.6 billion in 2026 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to increasing incidence of respiratory diseases, rising prevalence of pleural effusion and mesothelioma, wider availability of diagnostic imaging, expansion of pulmonology services, growth in hospital-based respiratory care.

Download a free sample of the pleural diseases market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=22099&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Emerging Companies in the Pleural Diseases Market
Several prominent organizations are making strong contributions to the pleural diseases market, including Pfizer Inc., Merck & Co. Inc., Bristol Myers Squibb Company, GSK plc, AstraZeneca plc, Koninklijke Philips N.V., Becton dic*kinson and Company, Boehringer Ingelheim International GmbH, Sanofi SA, Penn Medicine, Henry Ford Health, Dragerwerk AG, Emory Healthcare, Boston Medical Center, Cook Medical, WakeMed, Weill Cornell Medicine, Fox Chase Cancer Center, B. Braun SE, Bicakcilar, Redax S.p.a, and Rocket Medical.

A notable development occurred in October 2023 when US-based biopharmaceutical firm Aileron Therapeutics Inc. acquired Lung Therapeutics Inc. Although the acquisition amount was undisclosed, the deal bolsters Aileron's pipeline by incorporating LTI-03 for idiopathic pulmonary fibrosis (IPF) and LTI-01 for loculated pleural effusions (LPEs). Lung Therapeutics Inc. is known for its innovative peptide-based drugs targeting fibrosis and rare pulmonary disorders, expanding the focus on orphan pulmonary and fibrotic diseases.

View the full pleural diseases market report:
https://www.thebusinessresearchcompany.com/report/pleural-diseases-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Upcoming Trends Shaping the Pleural Diseases Market
Industry leaders are prioritizing the development of convenient, ready-to-use injectable treatments that simplify administration, reduce preparation times, and minimize dosing errors. These pre-formulated injections require no mixing or reconstitution, enhancing treatment accuracy and ease of use.

For example, in April 2024, Amneal Pharmaceuticals, a US-based drug manufacturer, launched PEMRYDI RTU, the first ready-to-use injectable form of pemetrexed. This innovation is significant for patients with pleural diseases, offering a more accessible and efficient treatment option while eliminating the need for additional preparation steps. It promises improved safety and helps streamline therapy for conditions such as malignant pleural mesothelioma.

Detailed Segmentation of the Global Pleural Diseases Market
This report categorizes the pleural diseases market into several key segments:

1) Disease Type:
- Pleurisy
- Pleural Effusion
- Pneumothelioma
- Mesothelioma
- Other Disease Types

2) Treatment Modalities:
- Medications
- Thoracentesis and Pleurodesis
- Minimally Invasive Interventions
- Surgical Interventions

3) Diagnostic Tools:
- Imaging Techniques
- Molecular Diagnostics
- Thoracoscopy
- Pleuroscopy

4) End User:
- Hospitals and Clinics
- Diagnostic Centers
- Research and Academic Institutions

Further breakdowns include:
- Pleurisy subcategories such as acute, chronic, infectious, and non-infectious pleurisy
- Pleural effusion types including transudative, exudative, malignant, parapneumonic, hemothorax, and chylothorax
- Pneumothelioma classifications like primary, secondary (metastatic), localized, and diffuse
- Mesothelioma types comprising pleural mesothelioma, benign pleural tumors, pleural thickening disorders, and pleural plaques
- Other disease types covering empyema, fibrothorax, pneumothorax, lung cancer, tuberculosis-related pleural disease, and sarcoidosis

This comprehensive segmentation provides a clear structure for understanding the diverse facets of pleural disease diagnosis, treatment, and patient care across different healthcare settings worldwide.

The 2026 edition of our market reports now delivers enhanced analytical coverage through market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, plus updated graphics and tables.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.